Researchers Developed Endometriosis Nanotherapy
Washington State University scientists created a targeted drug treatment that reduced endometriosis lesions in mice.
Updated on Sept. 26, 2026 in Women’s Health
Live Poll
Should medical researchers prioritize repurposing existing approved drugs to treat incurable diseases?
Researchers at Washington State University have developed a nanoparticle-based treatment for endometriosis, a condition that affects approximately 190 million women globally. The new approach uses a targeted delivery system to treat the disease without the fertility-related side effects of current hormonal therapies.
Why it matters
Endometriosis often requires hormonal treatments that can trigger menopause-like symptoms, negatively impacting bone density and fertility. This new method aims to provide a targeted alternative by delivering medication directly to disease-specific immune cells.
The study utilized a dendrimer nanoparticle to increase the solubility of niclosamide, a tapeworm drug. Researchers observed that the nanocarrier remained stable for two weeks and successfully reduced lesion size in mice following a single injection.
The players
Washington State University
This is a public research university based in Pullman, Washington, that facilitates various scientific and medical advancements.
The details
The treatment works by bonding niclosamide to a dendrimer molecule, which transports the medication directly to disease-specific immune cells at the site of tissue growth. This targeted delivery bypasses the systemic hormonal impacts commonly associated with standard endometriosis management.
Timeline
Washington State University announced the research findings on September 21, 2026.
The Big Picture
The study's inclusion in the Advanced Healthcare Materials journal follows the platform's focus on innovative biomedical engineering. This development marks a shift toward utilizing existing drug compounds through advanced nanotechnology to treat complex chronic conditions.
The development of this targeted treatment could eventually offer patients a way to manage endometriosis symptoms without the bone density or fertility issues linked to hormonal medications. While still in the research phase, this therapy represents a move toward more localized, precise medical intervention.
The takeaway
This breakthrough demonstrates the potential for repurposing existing, FDA-approved drugs by using nanotechnology to improve their delivery. Patients should monitor future clinical trial announcements as researchers move toward commercialization and human testing.
Further reading
For more information on current treatment trends, visit the Women’s Health section.
Source note: This article includes information reported by KOIN 6 Portland.
Live Poll
Should medical researchers prioritize repurposing existing approved drugs to treat incurable diseases?
